Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 65

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity

Viotti, J, Duplan, E, Caillava, C, Condat, J, Goiran, T, Giordano, C, Marie, Y, Idbaih, A, Delattre, J-Y, Honnorat, J, Checler, F, Alves da Costa, C·2014·Oncogene

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2013.124

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 47

  1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21: 2683–2710. · DOI · Paper page
  2. Bourdon JC, De Laurenzi V, Melino G, Lane DP . p53: 25 years of recherche and more questions to answer. Cell Death Differ 2003; 10: 397–399. · DOI
  3. Lane DP . Cancer. p53, guardian of the genome. Nature 1992; 358: 15–16. · DOI · Paper page
  4. Lim YP, Lim TT, Chan YL, Song AC, Yeo BH, Vojtesek B et al. The p53 knowledgebase: an integrated information resource for p53 research. Oncogene 2007; 26: 1517–1521. · DOI
  5. Asker C, Wiman KG, Selivanova G . p53-induced apoptosis as a safeguard against cancer. Biochem Biophys Res Commun 1999; 265: 1–6. · DOI
  6. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P . p53 mutations in nonastrocytic human brain tumors. Cancer Res 1991; 51: 6202–6205.
  7. Nayak A, Ralte AM, Sharma MC, Singh VP, Mahapatra AK, Mehta VS et al. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. Neurol India 2004; 52: 228–232.
  8. Ohgaki H, Kleihues P . Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170: 1445–1453. · DOI · Paper page
  9. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997; 56: 1098–1104. · DOI · Paper page
  10. Deguin-Chambon V, Vacher M, Jullien M, May E, Bourdon JC . Direct transactivation of c-Ha-Ras gene by p53: evidence for its involvement in p53 transactivation activity and p53-mediated apoptosis. Oncogene 2000; 19: 5831–5841. · DOI
  11. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci USA 2003; 100: 5956–5961. · DOI · Paper page
  12. Letessier A, Garrido-Urbani S, Ginestier C, Fournier G, Esterni B, Monville F et al. Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene 2007; 26: 298–307. · DOI
  13. Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci USA 2010; 107: 15145–15150. · DOI · Paper page
  14. Fujiwara M, Marusawa H, Wang HQ, Iwai A, Ikeuchi K, Imai Y et al. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene 2008; 27: 6002–6011. · DOI · Paper page
  15. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 2010; 42: 77–82. · DOI · Paper page
  16. da Costa CA, Sunyach C, Giaime E, West A, Corti O, Brice A et al. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol 2009; 11: 1370–1375. · DOI · Paper page
  17. Rotter V . p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. Proc Natl Acad Sci USA 1983; 80: 2613–2617. · DOI
  18. Miyashita T, reed JC . Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293–299. · DOI · Paper page
  19. Miyashita T, Harigai M, Hanada M, Reed JC . Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54: 3131–3135.
  20. Basu A, Haldar S . The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod 1998; 4: 1099–1109. · DOI · Paper page
  21. Hemann MT, Lowe SW . The p53-Bcl-2 connection. Cell Death Differ 2006; 13: 1256–1259. · DOI · Paper page
  22. Zinkel S, Gross A, Yang E . BCL2 family in DNA damage and cell cycle control. Cell Death Differ 2006; 13: 1351–1359. · DOI · Paper page
  23. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799–1805.
  24. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997; 3: 523–530.
  25. Nozaki M, Tada M, Kobayashi H, Zhang CL, Sawamura Y, Abe H et al. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro Oncol 1999; 1: 124–137. · DOI
  26. Wang F, Denison S, Lai JP, Philips LA, Montoya D, Kock N et al. Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer 2004; 40: 85–96. · DOI
  27. Henn IH, Gostner JM, Lackner P, Tatzelt J, Winklhofer KF . Pathogenic mutations inactivate parkin by distinct mechanisms. J Neurochem 2005; 92: 114–122. · DOI
  28. Soussi T, Hamroun D, Hjortsberg L, Rubio-Nevado JM, Fournier JL, Beroud C . MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer. Hum Mutat 2010; 31: 1020–1025. · DOI
  29. Edlund K, Larsson O, Ameur A, Bunikis I, Gyllensten U, Leroy B et al. Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci USA 2012; 109: 9551–9556. · DOI
  30. Costa SL, Paillaud E, Fages C, Rochette-Egly C, Plassat JL, Jouault H et al. Effects of a novel synthetic retinoid on malignant glioma in vitro: inhibition of cell proliferation, induction of apoptosis and differentiation. Eur J Cancer 2001; 37: 520–530. · DOI
  31. Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E et al. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 1997; 25: 151–157. · DOI · Paper page
  32. Ginsberg D, Oren M, Yaniv M, Piette J . Protein-binding elements in the promoter region of the mouse p53 gene. Oncogene 1990; 5: 1285–1290.
  33. Zhang C, Lin M, Wu R, Wang X, Yang B, Levine AJ et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc Natl Acad Sci USA 2011; 108: 16259–16264. · DOI · Paper page
  34. Picchio MC, Martin ES, Cesari R, Calin GA, Yendamuri S, Kuroki T et al. Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res 2004; 10: 2720–2724. · DOI
  35. Agirre X, Roman-Gomez J, Vazquez I, Jimenez-Velasco A, Garate L, Montiel-Duarte C et al. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer 2006; 118: 1945–1953. · DOI
  36. Fulci G, Ishii N, Van Meir EG . p53 and brain tumors: from gene mutations to gene therapy. Brain Pathol 1998; 8: 599–613. · DOI
  37. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H . Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6: 217–223 discussion 23-4. · DOI · Paper page
  38. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743–5750. · DOI · Paper page
  39. Sigal A, Rotter V . Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000; 60: 6788–6793.
  40. Haupt Y, Maya R, Kazaz A, Oren M . Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296–299. · DOI · Paper page
  41. Midgley CA, Lane DP . p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 1997; 15: 1179–1189. · DOI · Paper page
  42. Hollstein M, Sidransky D, Vogelstein B, Harris CC . p53 mutations in human cancers. Science 1991; 253: 49–53. · DOI · Paper page
  43. Yeo CW, Ng FS, Chai C, Tan JM, Koh GR, Chong YK et al. Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival. Cancer Res 2012; 72: 2543–2553. · DOI
  44. Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves da costa C, Vincent B et al. Presenilin-dependent transcriptional control of the Aβ-degrading enzyme neprilysin by intracellular domains of β APP and APLP. Neuron 2005; 46: 541–554. · DOI · Paper page
  45. West AB, Lockhart PJ, O'Farell C, Farrer MJ . Identification of a novel gene linked to parkin via a bi-directional promoter. J Mol Biol 2003; 326: 11–19. · DOI
  46. Idbaih A, Marie Y, Pierron G, Brennetot C, Hoang-Xuan K, Kujas M et al. Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 2005; 58: 483–487. · DOI · Paper page
  47. Idbaih A, Marie Y, Lucchesi C, Pierron G, Manie E, Raynal V et al. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer 2008; 122: 1778–1786. · DOI

Cited by

See all 65

Metadata

Authors
Viotti, J., Duplan, E., Caillava, C., Condat, J., Goiran, T., Giordano, C., Marie, Y., Idbaih, A., Delattre, J.-Y., Honnorat, J., Checler, F., & Alves da Costa, C.
Venue
Oncogene
Published
2013-05-06
Volume
33
Issue
14
Pages
1764-1775
ISSN
  • 0950-9232
  • 1476-5594
Cited by
65
References
6
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity. https://app.cochat.ai/papers/10.1038/onc.2013.124
The paper
Viotti, J., Duplan, E., Caillava, C., Condat, J., Goiran, T., Giordano, C., Marie, Y., Idbaih, A., Delattre, J.-Y., Honnorat, J., Checler, F., & Alves da Costa, C. (2014). Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity. Oncogene. https://doi.org/10.1038/onc.2013.124

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.